Molecule intelOpportunity: LowerEssential

Natamycin

24 brands · 12 companies · product forms

ATC: A01AB10, A07AA03, D01AA02, G01AA02, S01AA10

Opportunity snapshot

Launch attractiveness
27
Market saturation
33
Price room
15
Regulatory risk
0
24
brands
12
companies
Rs 324.3
median price
19
price points
1.59x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 13%

Price room

Across observed sources and strengths
CheapestRs 245.48
MedianRs 324.3
Most expensiveRs 389.13
Spread1.59×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 1.59x across 19 trusted points (Rs 245.48-389.13). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 8 live products for Natamycin — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(15) + 20% low-competition(67) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

12 canonical companies and 24 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 1.59x across 19 trusted points (Rs 245.48-389.13). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.